Literature DB >> 10888600

Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas.

D H Gutmann1, J Donahoe, A Perry, N Lemke, K Gorse, K Kittiniyom, S A Rempel, J A Gutierrez, I F Newsham.   

Abstract

Meningiomas are common nervous system tumors, whose molecular pathogenesis is poorly understood. To date, the most frequent genetic alteration detected in these tumors is loss of heterozygosity (LOH) on chromosome 22q. This finding led to the identification of the neurofibromatosis 2 (NF2) tumor suppressor gene on 22q12, which is inactivated in 40% of sporadic meningiomas. The NF2 gene product, merlin (or schwannomin), is a member of the protein 4.1 family of membrane-associated proteins, which also includes ezrin, radixin and moesin. Recently, we identified another protein 4.1 gene, DAL-1 (differentially expressed in adenocarcinoma of the lung) located on chromosome 18p11.3, which is lost in approximately 60% of non-small cell lung carcinomas, and exhibits growth-suppressing properties in lung cancer cell lines. Given the homology between DAL-1 and NF2 and the identification of significant LOH in the region of DAL-1 in lung, breast and brain tumors, we investigated the possibility that loss of expression of DAL-1 was important for meningioma development. In this report, we demonstrate DAL-1 loss in 60% of sporadic meningiomas using LOH, RT-PCR, western blot and immunohistochemistry analyses. Analogous to merlin, we show that DAL-1 loss is an early event in meningioma tumorigenesis, suggesting that these two protein 4.1 family members are critical growth regulators in the pathogenesis of meningiomas. Furthermore, our work supports the emerging notion that membrane-associated alterations are important in the early stages of neoplastic transformation and the study of such alterations may elucidate the mechanism of tumorigenesis shared by other tumor types.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888600     DOI: 10.1093/hmg/9.10.1495

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  46 in total

Review 1.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

Review 2.  The spectrin-ankyrin-4.1-adducin membrane skeleton: adapting eukaryotic cells to the demands of animal life.

Authors:  Anthony J Baines
Journal:  Protoplasma       Date:  2010-07-29       Impact factor: 3.356

3.  Alternative polyadenylation in a family of paralogous EPB41 genes generates protein 4.1 diversity.

Authors:  Laura Rangel; Eva Lospitao; Ana Ruiz-Sáenz; Miguel A Alonso; Isabel Correas
Journal:  RNA Biol       Date:  2016-12-16       Impact factor: 4.652

4.  Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Authors:  Michel Kalamarides; Michiko Niwa-Kawakita; Hélène Leblois; Vincent Abramowski; Michel Perricaudet; Anne Janin; Gilles Thomas; David H Gutmann; Marco Giovannini
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

Review 5.  Tumor suppressor role of protein 4.1B/DAL-1.

Authors:  Zi Wang; Ji Zhang; Mao Ye; Min Zhu; Bin Zhang; Mridul Roy; Jing Liu; Xiuli An
Journal:  Cell Mol Life Sci       Date:  2014-09-03       Impact factor: 9.261

6.  Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.

Authors:  Mark A Watson; David H Gutmann; Kelly Peterson; Michael R Chicoine; Bette K Kleinschmidt-DeMasters; Henry G Brown; Arie Perry
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Genomic landscape of meningiomas.

Authors:  Yohan Lee; Jason Liu; Shilpa Patel; Timothy Cloughesy; Albert Lai; Haumith Farooqi; David Seligson; Jun Dong; Linda Liau; Donald Becker; Paul Mischel; Soheil Shams; Stanley Nelson
Journal:  Brain Pathol       Date:  2009-11-20       Impact factor: 6.508

Review 8.  Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Authors:  Rosaria Viola Abbritti; Francesca Polito; Maria Cucinotta; Claudio Lo Giudice; Maria Caffo; Chiara Tomasello; Antonino Germanò; Mohammed Aguennouz
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

Review 9.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

10.  4.1N is involved in a flotillin-1/β-catenin/Wnt pathway and suppresses cell proliferation and migration in non-small cell lung cancer cell lines.

Authors:  Qin Yang; Min Zhu; Zi Wang; Hui Li; Weihua Zhou; Xiaojuan Xiao; Bin Zhang; Weixin Hu; Jing Liu
Journal:  Tumour Biol       Date:  2016-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.